• 1
    Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, for the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 134760.
  • 2
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 21723.
  • 3
    Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension and blood pressure levels in 6 European countries, Canada, and the US. JAMA 2003; 289: 23639.
  • 4
    American Medical Association. Report 2 of the Council on Scientific Affairs (A-04). Impact of drug formularies and therapeutic interchange on health outcomes. 2004. Available at (last accessed 29 April 2009).
  • 5
    American College of Cardiology. Position statement. Therapeutic substitution. 1988. Available at (last accessed 29 April 2009).
  • 6
    Department of Health. The proposals to implement ‘Generic Substitution’ in primary care, further to the Pharmaceutical Price Regulation Scheme (PRRS). 2009. London, UK: Department of Health, 5 January 2010. Available at (last accessed 15 January 2010).
  • 7
    Uber PA, Ross HJ, Zuckermann AO, Sweet SC, Corris PA, McNeil K, Mehra MR. Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory. J Heart Lung Transplant 2009; 28: 65560.
  • 8
    Morgan S, Hanley G, Greyson D. Comparison of tiered formularies and reference pricing policies: a systematic review. Open Med 2009; 3: 1319. Available at (last accessed 6 January 2010).
  • 9 What is ‘step therapy’? July 2009. Available at (last accessed 6 January 2010).
  • 10
    Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 2007; 81: 1728.
  • 11
    Belsey D. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen. Curr Med Res Opin 2008; 24: 5819.
  • 12
    Degli Esposti L, Di Martino M, Saragoni S, Sgreccia A, Capone A, Buda S, Esposti ED. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens 2004; 6: 7684.
  • 13
    Stankus V, Hemmelgarn B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT. Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009; 16: e1515.
  • 14
    Leicestershire Medicines Strategy Group. Leicestershire ACE inhibitor/ARB Choices for Primary Care 2008. Available at (last accessed 10 June 2009).
  • 15
    Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care 2007, 13 (Suppl. 3): S805.
  • 16
    Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, Dawes M, Ebbs D, Farmer A, Robinson J. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994; 12: 105360.
  • 17
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 202231.
  • 18
    Stergiou GS, Karotsis AK, Symeonidis A, Vassilopoulou VA. Aggressive blood pressure control in general practice (ABC-GP) study: can the new targets be reached? J Hum Hypertens 2003; 17: 76773.
  • 19
    Cote BR, Petersen EA. Impact of therapeutic switching in long-term care. Am J Manag Care 2008, 14 (11 Suppl.): SP238.
  • 20
    Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48: 38591.
  • 21
    Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 9951003.
  • 22
    Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895906.
  • 23
    Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 175562.
  • 24
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002; 288: 298197.
  • 25
    Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 154759.
  • 26
    Henwood SQ, De Villiers MM, Liebenberg W, Lötter AP. Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev Ind Pharm 2000; 26: 4038.
  • 27
    Pruszydlo MG, Quinzler R, Kaltschmidt J, Haefeli WE. Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany. Dtsch Med Wochenschr 2008; 133: 14238.
  • 28
    Tayrouz Y, Ding R, Burhenne J, Riedel KD, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 2003; 73: 397405.
  • 29
    Wandel C, Kim RB, Stein CM. ‘Inactive’ excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther 2003; 73: 3946.
  • 30
    Ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, Figg WD, Sparreboom A. Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. Clin Pharmacol Ther 2003; 74: 50910.
  • 31
    National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (partial update of NICE clinical guideline 18). 2006. Available at (last accessed 16 June 2009).
  • 32
    Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 1629.
  • 33
    Bos H, Andersen S, Rossing P, De Zeeuw D, Parving HH, De Jong PE, Navis G. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl 2000; 75: S327.
  • 34
    Sever PS, Chang CL. Discordant responses to two classes of drugs acting on the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst 2001; 2: 2530.
  • 35
    Stergiou GS, Skeva II, Baibas NM, Kalkana CB, Roussias LG, Mountokalakis TD. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism? Am J Hypertens 2001; 14: 68893.
  • 36
    Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Intraindividual blood pressure responses to angiotensin-converting enzyme inhibition and angiotensin receptor blockade. J Clin Hypertens 2005; 7: 1823.
  • 37
    Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 2006; 8: 2618.
  • 38
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 14553.
  • 39
    Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59: 8638.
  • 40
    Luque CA, Vazquez Ortiz M. Treatment of ACE inhibitor-induced cough. Pharmacotherapy 1999; 19: 80410.
  • 41
    Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S, for the British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004–BHS IV. J Hum Hypertens 2004; 18: 13985.
  • 42
    Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 90412.
  • 43
    Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 23442.
  • 44
    Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008; 51: 162430.
  • 45
    Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, Ewan PW. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260: 96770.
  • 46
    Vleeming W, Van Amsterdam JG, Stricker BH, De Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998; 18: 17188.
  • 47
    Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17: 10311.
  • 48
    Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2006; 8: 64956.
  • 49
    Irons BK, Kumar A. Valsartan-induced angioedema. Ann Pharmacother 2003; 37: 10247.
  • 50
    Kyrmizakis DE, Papadakis CE, Liolios AD, Karatzanis AD, Malandrakis S, Skoulakis CE, Bizakis JG, Velegrakis GA. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Arch Otolaryngol Head Neck Surg 2004; 130: 14169.
  • 51
    Lo KS. Angioedema associated with candesartan. Pharmacotherapy 2002; 22: 11769.
  • 52
    Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007; 98: 5763.
  • 53
    Nykamp D, Winter EE. Olmesartan medoxomil-induced angioedema. Ann Pharmacother 2007; 41: 51820.
  • 54
    Anon. Tolerability and quality of life in ARB-treated patients. Am J Manag Care 2005; 11 (Suppl.): S3924.
  • 55
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, Van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 110587.
  • 56
    Joint Formulary Committee. British National Formulary, 58 edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009.
  • 57
    McInnes GT, Stergiou GS. Clinical pharmacology of angiotensin converting enzyme inhibitors. In: Clinician's Guide to Angiotensin Converting Enzyme Inhibition, ed. ClelandJGF. London: Churchill Livingstone, 1993, 2336.
  • 58
    Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008; 62: 7687.
  • 59
    World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization, 2003.
  • 60
    Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 23945.
  • 61
    Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, Herings RM. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24: 1217.
  • 62
    Halpern MT, Khan ZM, Daley WL, Stewart WF. Impact of compliance (adherence) and persistence of treatment with valsartan on hypertension clinical outcomes. Value Health 2005; 8: A104.
  • 63
    Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19: 35762.
  • 64
    McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 21426.
  • 65
    Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 52130.
  • 66
    Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep 2002; 4: 42433.
  • 67
    Siiskonen SJ, Breekveldt-Postma NS, Vincze G, Khan ZM, Erkens JA, Herings RM. Higher persistence with valsartan compared with enalapril in daily practice. Vasc Health Risk Manag 2007; 3: 103944.
  • 68
    Thaker D, Frech F, Gause D, Zhang W. Patient compliance and persistency with antihypertensive agents: a comparison of agents in different therapeutic classes. Am J Hypertens 2005, 18 (Suppl. 4S): A222.
  • 69
    Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003; 9: 4249.
  • 70
    Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag 2008; 4: 2330.
  • 71
    Phillips B, Roberts C, Rudolph AE, Morant S, Aziz F, O'Regan CP. Switching statins: the impact on patient outcomes. Br J Cardiol 2007; 14: 2805.
  • 72
    Furberg CD, Psaty BM. Should evidence-based proof of drug efficacy be extrapolated to a ‘class of agents’? Circulation 2003; 108: 260810.
  • 73
    Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig 2007; 27: 73553.
  • 74
    Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 41826.
  • 75
    Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009; 63: 76675.
  • 76
    Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51: 161723.
  • 77
    Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 3350.
  • 78
    Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, for the VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 40311.
  • 79
    Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 100310.
  • 80
    Yang HY, Kao PF, Chen TH, Tomlinson B, Ko WC, Chan P. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients. J Clin Pharmacol 2007; 47: 397403.
  • 81
    Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23: 20715.
  • 82
    Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995; 23: 2859.
  • 83
    Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62: 41725.
  • 84
    Williamson KM, Patterson JH, McQueen RH, Adams KF Jr, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998; 63: 31623.
  • 85
    Novartis Pharmaceuticals Corporation. Valsartan prescribing information. 2008. Available at (last accessed 15 June 2009).
  • 86
    Reiffel JA, Kowey PR. Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol 2000; 85: 11513.
  • 87
    Banahan BF III, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med 1997; 157: 20808.
  • 88
    Kirking DM, Gaither CA, Ascoine FJ, Welage LS. Physicians' individual and organizational views on generic medications. 2001. Available at (last accessed 12 June 2009).
  • 89
    Kovarik JM, Noe A, Wang Y, Mueller I, DeNucci G, Schmouder RL. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur J Clin Pharmacol 2006; 62: 3616.
  • 90
    Lima DM, Dos Santos LD, Lima EM. Stability and in vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications. J Pharm Biomed Anal 2008; 47: 9347.
  • 91
    Smith JC, Tarocco G, Merazzi F, Salzmann U. Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation? Curr Med Res Opin 2006; 22: 70920.
  • 92
    Vetchy D, Vetcha M, Rabiskova M, Gryczova E, Bartosikova L. Comparison of in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Medicina 2007; 43: 32631.
  • 93
    Lusina M, Cindrić T, Tomaić J, Peko M, Pozaić L, Musulin N. Stability study of losartan/hydrochlorothiazide tablets. Int J Pharm 2005; 291: 12737.
  • 94
    Nightingale CH. A survey of the quality of generic clarithromycin products from 18 countries. Clin Drug Investig 2005; 25: 13552.
  • 95
    Vial J, Cohen M, Sassiat P, Thiébaut D. Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. Curr Med Res Opin 2008; 24: 201933.
  • 96
    Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 2004; 34: 3418.
  • 97
    Hellström J, Rudholm N. Side effects of generic competition? Eur J Health Econ 2004; 5: 2038.
  • 98
    Food and Drug Administration. FDA issues warning letters to Ranbaxy Laboratories Ltd., and an import alert for drugs from two Ranbaxy plants in India. 2008. Available at (last accessed 12 June 2009).
  • 99
    Gerbino PP, Joseph AS. Multisource drugs: implications and concerns in the geriatric population. Hosp Pharm 1993; 28: 968, 101–2.
  • 100
    Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, Gleiter CH, Hummers-Pradier E. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 2005; 43: 4729.
  • 101
    Ganther JA, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc 2000; 40: 37883.
  • 102
    Kjoenniksen I, Lindbaek M, Granas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006; 28: 2849.
  • 103
    Harris Interactive. Consumers' views on therapeutic substitution. September 2008. Available at (last accessed 15 June 2009).
  • 104
    Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287: 6227.
  • 105
    Dowell JS, Snadden D, Dunbar JA. Changing to generic formulary: how one fundholding practice reduced prescribing costs. BMJ 1995; 310: 5058.
  • 106
    Van Wijk BL, Klungel OH, Heerdink ER, De Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006; 40: 1520.
  • 107
    Momani A, Odedina F, Rosenbluth S, Madhavan S. Drug-management strategies: consumers' perspectives. J Manag Care Pharm 2000; 6: 1228.
  • 108
    Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160: 416.
  • 109
    Thayer S, Dastani H. Can switching among the ARB class impact medical costs and medication adherence? J Manag Care Pharm 2009; 15: 179.
  • 110
    Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care 2005; 11: SP2734.
  • 111
    Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 2439.
  • 112
    Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005; 11: 6704.
  • 113
    Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumers' views on generic medications. J Am Pharm Assoc 2001; 41: 72936.
  • 114
    Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 4806.
  • 115
    Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27: 16109.
  • 116
    Lindholm LH, Kartman B, Carlberg B, Persson M, Svensson A, Samuelsson O. Cost implications of development of diabetes in the ALPINE study. J Hypertens Suppl 2006; 24: S6572.
  • 117
    Stafylas PC, Sarafidis PA, Grekas DM, Lasaridis AN. A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. J Clin Hypertens 2007; 9: 7519.
  • 118
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 27583.
  • 119
    Müller-Nordhorn J, Englert H, Wegscheider K, Berger H, Sonntag F, Völler H, Meyer-Sabellek W, Reinhold T, Windler E, Katus HA, Willich SN. Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany. Clin Res Cardiol 2008; 97: 1529.
  • 120
    Hilleman DE, Reyes AP, Wurdeman RL, Faulkner M. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. J Hum Hypertens 2001; 15: 55965.
  • 121
    Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 5337.
  • 122
    Lindgren-Furmaga EM, Schuna AA, Wolff NL, Goodfriend TL. Cost of switching hypertensive patients from enalapril maleate to lisinopril. Am J Hosp Pharm 1991; 48: 2769.
  • 123
    McDonough KP, Weaver RH, Viall GD. Enalapril to lisinopril: economic impact of a voluntary angiotensin-converting enzyme-inhibitor substitution program in a staff-model health maintenance organization. Ann Pharmacother 1992; 26: 399404.
  • 124
    Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care 2005; 11: SP3542.
  • 125
    Plauschinat CA, Wogen J, Gause D, Zhang W. Economic implications of switching antihypertensive drugs within the same therapeutic class. J Manag Care Pharm 2004; 10: 466.
  • 126
    Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract 1999; 12: 10514.
  • 127
    Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002; 346: 8229.
  • 128
    Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther 2003; 74: 388400.
  • 129
    Stafilas PC, Sarafidis PA, Lasaridis AN, Aletras VH, Niakas DA. An economic evaluation of the 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. Am J Hypertens 2005; 18: 123340.
  • 130
    Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract 2007; 61: 1523.
  • 131
    Patel RJ, Gray DR, Pierce R, Jafari M. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center. Am J Manag Care 1999; 5: 46574.
  • 132
    Ito MK, Lin JC, Morreale AP, Marcus DB, Shabetai R, Dresselhaus TR, Henry RR. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. Am J Health Syst Pharm 2001; 58: 17349.
  • 133
    Meissner B, Dickson M, Shinogle J, Reeder CE, Belazi D, Senevirante V. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm 2006; 12: 33140.
  • 134
    Moisan J, Vaillancourt R, Grégoire JP, Gaudet M, Côté I, Leach A. Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes. Am J Health Syst Pharm 1999; 56: 143741.
  • 135
    Taylor AJ, Grace K, Swiecki J, Hyatt R, Gibbs H, Sheikh M, O'Malley PG, Lowenthal SP, West M, Spain J, Maneval K, Jones DL. Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy 2001; 21: 11309.
  • 136
    Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007; 48: 4649.
  • 137
    Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. Lancet 2002; 359: 212930.
  • 138
    Mar J, Rodríguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001; 19: 14955.
  • 139
    McIntyre H, Costa FV, Düsing R, Ambrosioni E, Gerth W. The role of losartan in cost-effective hypertension control. Curr Med Res Opin 2002; 18: 13945.
  • 140
    Sclar DA, Skaer TL, Robison LM, Chin A, Okamoto MP, Nakahiro RK, Gill MA. Effect of antihypertensive formulation on health service expenditures. Clin Auton Res 1993; 3: 3638.
  • 141
    Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19: 144657.
  • 142
    Rizzo JA, Abbott TA III, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996; 5: 24965.
  • 143
    Skaer TL, Sclar DA, Robison LM, Chin A, Gill MA, Okamoto MP, Nakahiro RK. Effect of pharmaceutical formulation for antihypertensive therapy on health service utilization. Clin Ther 1993; 15: 71525.
  • 144
    Sun SX, Ye X, Lee KY, Dupclay L Jr, Plauschinat C. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction. Clin Ther 2008; 30: 221727.
  • 145
    Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care 2009; 15: 12331.
  • 146
    Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm 2007; 13: 23544.
  • 147
    Skinner BJ, Gray JR, Attara GP. Increased health costs from mandated therapeutic substitution of proton pump inhibitors in British Columbia. Aliment Pharmacol Ther 2009; 29: 88291.
  • 148
    Johnston A. Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Curr Med Res Opin 2010; 26: 8718.